AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$CYRX

Cryoport Reports Second Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CYRX
Bullish
medium confidence
Mentioned
$CYRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CYRXBullishMed
01

Why it matters

Traders can update CYRX’s growth mix (services up, products flat) and incorporate the stated adjusted EBITDA inflection when reassessing margin trajectory and operating leverage.

02

Market read

The quarter’s revenue growth and the claim of positive adjusted EBITDA are the key new datapoints for CYRX’s near-term valuation and margin expectations.

03

What to watch

The filing references upcoming facility/network expansion and product launches, but does not quantify margin guidance or near-term capex, leaving execution risk.

Relevance 7/10Novelty 7/10Timing: filed after market close, for next-session earnings-model repricing

Background

This is Cryoport’s SEC 8-K with Exhibit 99.1 covering Q2 and H1 2026 results and operational milestones tied to its temperature-controlled supply chain for life sciences and CGT.

Company-level read

Ticker impact

$CYRXBullishMedium confidence
Context

Cryoport reported Q2 2026 revenue of $49.0M (+8% YoY) and said it achieved positive adjusted EBITDA in the quarter.

Expected impact

Likely positive bias for CYRX as traders focus on adjusted EBITDA turning positive and continued CGT-related demand.

Evidence & confidence

The filing provides concrete quarterly revenue by segment, CGT trial/support metrics, and a stated adjusted EBITDA milestone, all of which are actionable for earnings-model updates.

Market effects

Sector

Supports the CGT supply-chain services growth narrative and may lift sentiment toward temperature-controlled logistics providers.

Regional

No specific regional macro impact beyond planned facility launches in Paris and Santa Ana.

Global

Global clinical-trial support metrics reinforce demand tied to worldwide CGT pipeline expansion.

Counterpoint

What could challenge this read

Positive adjusted EBITDA may not translate to sustainable GAAP profitability, and Life Sciences Products revenue was flat year over year.

Key entities

  • company
    Cryoport, Inc.

    NASDAQ-listed temperature-controlled supply chain provider for life sciences and CGT; reported Q2 2026 results and adjusted EBITDA milestone.

  • customer
    Orca Bio

    Cryoport customer referenced as receiving FDA approval for TREGZI during Q2 2026.

  • customer
    Vertex Pharmaceuticals

    Cryoport customer referenced as receiving FDA supplemental approval for CASGEVY during Q2 2026.

  • customer
    Verismo Therapeutics

    Referenced as selecting Cryoport Systems’ IntegriCell cryopreservation services.

Read at source← All news

Related articles

$CYRXMed

CryoPort Q3 Earnings Call Highlights

CryoPort reported Q3 supporting 23 commercial therapies and 788 clinical trials. China operations contribute 3-4% of revenue. The company expects five regulatory filings and two potential new therapy approvals in 2026. Guidance is conservative, focusing on existing clients. Expansion plans include new BioServices capabilities in Paris and California, with long-term margin goals of 55% gross and 30% adjusted EBITDA.

finance.yahoo.com
$CYRXMed

Cryoport Reports Third Quarter 2026 Financial Results

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Third Quarter 2026 Financial Results · Third quarter revenue grew 14% year-over-year to $50.2 million · Commercial Cell and Gene Therapy revenue increased 20% year-over-year · Supporting a record 788 global clinical trials and 23 commercially approve

SEC EDGAR 8-K
$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

yahoo.com
$RVMDMedAI 8/10

Why is Revolution Medicines stock surging today?

Revolution Medicines (RVMD) stock rose 7% after reporting Q3 revenue of $197.6M, exceeding estimates, driven by its new drug RASONQUE. Analysts raised price targets, with HC Wainwright setting a $350 target. The company has strong cash reserves and reaffirmed its 2026 expense guidance. NASDAQ and S&P 500 gains provided a supportive market backdrop.

investing.com
HighAI 9/10

Why is Ubiquiti stock surging today?

Ubiquiti's stock rose 16.9% after reporting fiscal Q1 2027 results. Revenue was $1.026 billion, beating estimates, with GAAP EPS of $5.29. The Enterprise Technology segment drove growth. The company declared a $1.00 dividend. Analysts have mixed views, with a consensus price target of $734.50. The broader market also gained.

investing.com
$DVNHighAI 8/10

Devon Energy 3Q 2026: Revenue $6.86B, EPS $0.88 — 10-Q Summary

Devon Energy reported Q3 2026 revenue of $6.86B, up 58.4% YoY, and net income of $1.01B, up 46.7% YoY. EPS was $0.88, down 19.3% YoY. Production increased to 1,668 MBoe/d. The company repurchased $415M in shares, paid $366M in dividends, and expects $1B in annual synergies by 2027. It also agreed to sell Eagle Ford assets for $4.2B, closing expected in early 2027.

tradingview.com